PSYB.H — Psybio Therapeutics Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual income statement for Psybio Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 June 30th | 2019 June 30th | 2020 June 30th | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.041 | 0.021 | 0.016 | 11 | 4.73 |
Operating Profit | -0.041 | -0.021 | -0.016 | -11 | -4.73 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.041 | -0.021 | -0.016 | -11 | -4.89 |
Net Income After Taxes | -0.041 | -0.021 | -0.016 | -11 | -4.89 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.041 | -0.021 | -0.016 | -11 | -4.89 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.041 | -0.021 | -0.016 | -11 | -4.89 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.018 | -0.009 | -0.007 | -0.09 | -0.044 |